About
Alex Aliper, PhD, is co-founder and president of Insilico Medicine, a clinical-stage AI-driven biotechnology company focused on drug discovery. His public profile centers on applying AI to multi-omics, generative chemistry, and clinical-trial prediction, including work on aging-related diseases and longevity research. Public sources portray him as an operating biotech executive and scientific leader rather than a fund manager or documented personal investor.
Areas of interest
biotechdrug discoveryartificial intelligencecomputational biologygenerative chemistrygenerative biologyclinical trial predictionaging researchlongevity